Of the remaining 493 LUAD cases, the three studies showed no fusions involving any of the recurrent genes, while SplitFusion detected two cases with SLC34A2::ROS1 fusion (Tables 1 and S4; Figure S9), an indication for ROS1-targeted therapy in lung cancer patients. This evidence concerns the gene SLC34A2 and lung carcinoma.